亚盛医药在2024年实现营收9.81亿元,同比增长342%,净亏损收窄至4.05亿元。其核心产品耐立克®(奥雷巴替尼)销售收入达2.41亿元,同比增长52%。该药物作为中国首个获批治疗T315I突变慢性髓细胞白血病的BCR-ABL1 TKI,已在734家医院和DTP药房落地。亚盛医药通过国际临床试验推进、创纪录BD达成及美股上市等举措,正逐步迈向全球肿瘤创新领域的领导者地位。公司董事长杨大俊博士...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.